Nyxoah is a Belgian sleep-apnea implant company whose first year of United States commercialization is now a share-gain test against a much larger incumbent, not an approval story. The Food and Drug Administration cleared the Genio system in August 2025 as the first bilateral hypoglossal nerve stimulator available in the country. That clearance converted a European-marked device into a Nasdaq-listed commercial launch. The equity debate is whether account activation and prior-authorization conversion compound fast enough to justify a second-half sales-force build after a heavily dilutive recapitalization.
The June recapitalization priced ordinary shares at $1.72. A European Investment Bank draw sat alongside that offering and brought new capital to about $110 million. Cash and financial assets then stood near €98 million. That pile funds the United States build that the company had almost exhausted. The share count roughly doubled, so the residual claim is now a much larger float against a still-loss-making launch. Sequential United States revenue rose in the second quarter, and active high-volume accounts doubled. That is real commercial motion. It is also still a rounding error next to Inspire Medical Systems, whose annual sales sit near a billion.
Second-quarter global sales reached €7.7 million, with the United States contributing €5.2 million. Prior-authorization patients entering the third quarter rose to 427. Management still guides full-year sales of €36 million to €40 million. Hitting that range requires a sharp second-half acceleration just as the board searches for a United States-based chief executive and Inspire presses a Delaware patent case set for trial in late 2027. The question for the next two prints is whether utilization inside already-opened accounts compounds, or whether the launch remains a funded option on share that the incumbent still owns.